{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:34:14Z","timestamp":1740126854376,"version":"3.37.3"},"reference-count":229,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Neurol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In this article, we review prevention of serious adverse clinical outcomes and treatment side effects in patients with neuromuscular disorders including myopathies and myasthenia gravis. While neither of these entities is preventable, their course can often be modified, and severe sequelae may be prevented, with the identification of risk factors and proactive attention toward treatment planning.<\/jats:p>","DOI":"10.1055\/s-0042-1758779","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:05:30Z","timestamp":1668816330000},"page":"594-610","source":"Crossref","is-referenced-by-count":0,"title":["Prevention of Adverse Outcomes and Treatment Side Effects in Patients with Neuromuscular Disorders"],"prefix":"10.1055","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9608-9243","authenticated-orcid":false,"given":"Kavita M.","family":"Grover","sequence":"additional","affiliation":[{"name":"Department of Neurology, Henry Ford Medical Group, Wayne State University, Detroit, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naganand","family":"Sripathi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Henry Ford Medical Group, Wayne State University, Detroit, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"issue":"08","key":"ref1","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1212\/01.wnl.0000239826.63523.8e","article-title":"Early development of critical illness myopathy and neuropathy in patients with severe sepsis","volume":"67","author":"J Khan","year":"2006","journal-title":"Neurology"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1212\/WNL.46.3.731","article-title":"Muscle is electrically inexcitable in acute quadriplegic myopathy","volume":"46","author":"M M Rich","year":"1996","journal-title":"Neurology"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/(SICI)1097-4598(199703)20:3<316::AID-MUS8>3.0.CO;2-E","article-title":"Acute quadriplegic myopathy: analysis of myosin isoforms and evidence for calpain-mediated proteolysis","volume":"20","author":"C J Showalter","year":"1997","journal-title":"Muscle Nerve"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1007\/s00134-007-0772-2","article-title":"Neuromuscular dysfunction acquired in critical illness: a systematic review","volume":"33","author":"R D Stevens","year":"2007","journal-title":"Intensive Care Med"},{"issue":"05","key":"ref5","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1152\/japplphysiol.00019.2021","article-title":"Pathophysiology and management of critical illness polyneuropathy and myopathy","volume":"130","author":"K Cheung","year":"2021","journal-title":"J Appl Physiol"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/cc7100","article-title":"Clinical review: critical illness polyneuropathy and myopathy","volume":"12","author":"G Hermans","year":"2008","journal-title":"Crit Care"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/mus.24175","article-title":"Long-term recovery In critical illness myopathy is complete, contrary to polyneuropathy","volume":"50","author":"S Koch","year":"2014","journal-title":"Muscle Nerve"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12883-016-0775-0","article-title":"Critical illness polyneuropathy (CIP) in neurological early rehabilitation: clinical and neurophysiological features","volume":"16","author":"S B Schmidt","year":"2016","journal-title":"BMC Neurol"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1097\/CCM.0000000000001839","article-title":"Neuromuscular Blocking agents and neuromuscular dysfunction acquired in critical illness: A systematic review and meta-analysis","volume":"44","author":"D R Price","year":"2016","journal-title":"Crit Care Med"},{"issue":"01","key":"ref10","first-page":"CD006832","article-title":"Interventions for preventing critical illness polyneuropathy and critical illness myopathy","author":"G Hermans","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"09","key":"ref11","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1097\/CCM.0000000000003263","article-title":"Impact of very early physical therapy during septic shock on skeletal muscle: a randomized controlled trial","volume":"46","author":"C E Hickmann","year":"2018","journal-title":"Crit Care Med"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4103\/1673-5374.125337","article-title":"Critical illness polyneuropathy and myopathy: a systematic review","volume":"9","author":"C Zhou","year":"2014","journal-title":"Neural Regen Res"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clnu.2006.07.007","article-title":"Effect of an enteral diet supplemented with a specific blend of amino acid on plasma and muscle protein synthesis in ICU patients","volume":"26","author":"O Mansoor","year":"2007","journal-title":"Clin Nutr"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1096\/fj.201801857RRR","article-title":"Omega-3 fatty acid supplementation attenuates skeletal muscle disuse atrophy during two weeks of unilateral leg immobilization in healthy young women","volume":"33","author":"C McGlory","year":"2019","journal-title":"FASEB J"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1212\/WNL.61.3.288","article-title":"Unicorns, dragons, polymyositis, and other mythological beasts","volume":"61","author":"A A Amato","year":"2003","journal-title":"Neurology"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-180308","article-title":"Current classification and management of inflammatory myopathies","volume":"5","author":"J Schmidt","year":"2018","journal-title":"J Neuromuscul Dis"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/mus.23302","article-title":"Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan","volume":"45","author":"D E Furst","year":"2012","journal-title":"Muscle Nerve"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"K Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrrheum.2018.48","article-title":"Risk factors and disease mechanisms in myositis","volume":"14","author":"F W Miller","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"09","key":"ref20","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1001\/jamainternmed.2015.3528","article-title":"Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families","volume":"175","author":"C F Kuo","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s13075-016-1127-6","article-title":"Familial risk of systemic sclerosis and co-aggregation of autoimmune diseases in affected families","volume":"18","author":"C F Kuo","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"07","key":"ref22","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/gene.2015.28","article-title":"Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes","volume":"16","author":"F W Miller","year":"2015","journal-title":"Genes Immun"},{"issue":"08","key":"ref23","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/annrheumdis-2015-208119","article-title":"Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups","volume":"75","author":"S Rothwell","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"05","key":"ref24","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/art.40045","article-title":"Immune-array analysis in sporadic inclusion body myositis reveals HLA-DRB1 amino acid heterogeneity across the myositis spectrum","volume":"69","author":"S Rothwell","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jaut.2012.05.002","article-title":"Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop","volume":"39","author":"F W Miller","year":"2012","journal-title":"J Autoimmun"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/00002281-199305060-00004","article-title":"Noninfectious environmental agents associated with myopathies","volume":"5","author":"L A Love","year":"1993","journal-title":"Curr Opin Rheumatol"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0889-857X(02)00029-7","article-title":"Genetic and environmental risk factors for idiopathic inflammatory myopathies","volume":"28","author":"A M Reed","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"key":"ref28","first-page":"297","volume-title":"Non-infectious environmental agents and autoimmunity","author":"F W Miller","year":"2006","edition":"Vol. 4"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-60327-827-0_2","volume-title":"Classification of idiopathic inflammatory myopathies","author":"F W Miller","year":"2009"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/BOR.0b013e32834b5457","article-title":"State of the art: what we know about infectious agents and myositis","volume":"23","author":"L Gan","year":"2011","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1002\/art.30514","article-title":"Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan","volume":"63","author":"J A Allen","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"920","DOI":"10.7326\/0003-4819-118-12-199306150-00002","article-title":"Association between bovine collagen dermal implants and a dermatomyositis or a polymyositis-like syndrome","volume":"118","author":"J Cukier","year":"1993","journal-title":"Ann Intern Med"},{"issue":"11","key":"ref33","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1002\/art.20587","article-title":"Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops","volume":"50","author":"T O'Hanlon","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"08","key":"ref34","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.24702","article-title":"Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women","volume":"60","author":"L A Love","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"05","key":"ref35","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/art.39059","article-title":"Nested case-control study of selected systemic autoimmune diseases in World Trade Center rescue\/recovery workers","volume":"67","author":"M P Webber","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10067-013-2467-0","article-title":"Occupational exposure in patients with the antisynthetase syndrome","volume":"33","author":"A Labirua-Iturburu","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"03","key":"ref37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1212\/WNL.0000000000002291","article-title":"Hepatitis C virus infection in inclusion body myositis: a case-control study","volume":"86","author":"A Uruha","year":"2016","journal-title":"Neurology"},{"issue":"02","key":"ref38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/art.11002","article-title":"Human immunodeficiency virus-associated polymyositis: a longitudinal study of outcome","volume":"49","author":"R W Johnson","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"05","key":"ref39","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00296-009-1231-x","article-title":"Dermatomyositis and HIV infection: case report and review of the literature","volume":"31","author":"M B Carroll","year":"2011","journal-title":"Rheumatol Int"},{"issue":"05","key":"ref40","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/ana.21103","article-title":"Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells","volume":"61","author":"M C Dalakas","year":"2007","journal-title":"Ann Neurol"},{"issue":"01","key":"ref41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/nen.0b013e31815f38b7","article-title":"Inclusion body myositis associated with human T-lymphotropic virus-type I infection: eleven patients from an endemic area in Japan","volume":"67","author":"E Matsuura","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"issue":"06","key":"ref42","first-page":"1556","article-title":"Skeletal muscle pathology in 2 siblings infected with Toxoplasma gondii","volume":"27","author":"E E Calore","year":"2000","journal-title":"J Rheumatol"},{"issue":"11","key":"ref43","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1136\/annrheumdis-2017-211174","article-title":"Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based case-control study","volume":"76","author":"J Svensson","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"09","key":"ref44","first-page":"1218","article-title":"Predisposing factors in polymyositis-dermatomyositis: results of a nationwide survey","volume":"16","author":"M G Lyon","year":"1989","journal-title":"J Rheumatol"},{"issue":"05","key":"ref45","first-page":"995","article-title":"Penicillamine induced polymyositis and dermatomyositis","volume":"14","author":"G J Carroll","year":"1987","journal-title":"J Rheumatol"},{"issue":"10","key":"ref46","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/archderm.144.10.1341","article-title":"Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling","volume":"144","author":"A K Somani","year":"2008","journal-title":"Arch Dermatol"},{"issue":"10","key":"ref47","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"M Touat","year":"2018","journal-title":"Neurology"},{"issue":"39","key":"ref48","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1016\/j.vaccine.2018.08.036","article-title":"Aluminum in vaccines: Does it create a safety problem?","volume":"36","author":"N Principi","year":"2018","journal-title":"Vaccine"},{"issue":"10","key":"ref49","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/acr.22358","article-title":"Risk factors for juvenile dermatomyositis: exposure to tobacco and air pollutants during pregnancy","volume":"66","author":"M A Orione","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"06","key":"ref50","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/annrheumdis-2011-200182","article-title":"Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study","volume":"71","author":"H Chinoy","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"05","key":"ref51","doi-asserted-by":"crossref","first-page":"e0154746","DOI":"10.1371\/journal.pone.0154746","article-title":"Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies","volume":"11","author":"N Mugii","year":"2016","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1196\/annals.1361.047","article-title":"Cancer-associated myositis: clinical features and prognostic signs","volume":"1051","author":"A Ponyi","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"ref53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-020-00950-3","article-title":"Impact and management of dysphagia in inflammatory myopathies","volume":"22","author":"R Zeng","year":"2020","journal-title":"Curr Rheumatol Rep"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","article-title":"The EuroMyositis registry: an international collaborative tool to facilitate myositis research","volume":"77","author":"J B Lilleker","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"08","key":"ref55","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1136\/annrheumdis-2013-205127","article-title":"Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort","volume":"74","author":"C Dobloug","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"ref56","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/acr.20325","article-title":"Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients","volume":"62","author":"I Marie","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"04","key":"ref57","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4065\/82.4.441","article-title":"Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients","volume":"82","author":"T H Oh","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"08","key":"ref58","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.apmr.2012.02.010","article-title":"The effects of lingual intervention in a patient with inclusion body myositis and Sj\u00f6gren's syndrome: a longitudinal case study","volume":"93","author":"G A Malandraki","year":"2012","journal-title":"Arch Phys Med Rehabil"},{"issue":"04","key":"ref59","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1288\/00005537-198704000-00014","article-title":"Function in the pharyngoesophageal segment","volume":"97","author":"M S Mendelsohn","year":"1987","journal-title":"Laryngoscope"},{"key":"ref60","first-page":"G450","article-title":"Volitional augmentation of upper esophageal sphincter opening during swallowing","volume":"260","author":"P J Kahrilas","year":"1991","journal-title":"Am J Physiol"},{"issue":"07","key":"ref61","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1080\/02841850600774043","article-title":"Effects of three different swallow maneuvers analyzed by videomanometry","volume":"47","author":"K Bod\u00e9n","year":"2006","journal-title":"Acta Radiol"},{"issue":"01","key":"ref62","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12877-018-0839-7","article-title":"Use of modified diets to prevent aspiration in oropharyngeal dysphagia: is current practice justified?","volume":"18","author":"S T O'Keeffe","year":"2018","journal-title":"BMC Geriatr"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jns.2017.07.031","article-title":"Botulinum toxin alleviates dysphagia of patients with inclusion body myositis","volume":"380","author":"A Schrey","year":"2017","journal-title":"J Neurol Sci"},{"issue":"01","key":"ref64","first-page":"165","article-title":"Prognosis of dysphagia in dermatomyositis","volume":"37","author":"M Ogawa-Momohara","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"03","key":"ref65","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","article-title":"Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial","volume":"22","author":"N Miyasaka","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"12","key":"ref66","first-page":"2706","article-title":"Intravenous immunoglobulins as treatment of life threatening esophageal involvement in polymyositis and dermatomyositis","volume":"26","author":"I Marie","year":"1999","journal-title":"J Rheumatol"},{"issue":"03","key":"ref67","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"M C Dalakas","year":"1997","journal-title":"Neurology"},{"issue":"06","key":"ref68","first-page":"838","article-title":"Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients","volume":"30","author":"C Dobloug","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"03","key":"ref69","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000441490","article-title":"Subcutaneous immunoglobulin use in inclusion body myositis: a review of 6 cases","volume":"7","author":"P Cherin","year":"2015","journal-title":"Case Rep Neurol"},{"issue":"11","key":"ref70","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/PHM.0b013e31818a50e2","article-title":"Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome","volume":"87","author":"T H Oh","year":"2008","journal-title":"Am J Phys Med Rehabil"},{"key":"ref71","first-page":"1","article-title":"Balloon dilation in sporadic inclusion body myositis patients with dysphagia","volume":"6","author":"K-Y Murata","year":"2013","journal-title":"Clin Med Insights Case Rep"},{"issue":"01","key":"ref72","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/000348949410300105","article-title":"Treatment of dysfunction of the cricopharyngeal muscle with botulinum A toxin: introduction of a new, noninvasive method","volume":"103","author":"I Schneider","year":"1994","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"02","key":"ref73","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/000348941312200205","article-title":"Botulinum toxin injection for the treatment of upper esophageal sphincter dysfunction","volume":"122","author":"E A Kelly","year":"2013","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"04","key":"ref74","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1017\/S031716710002953X","article-title":"Inclusion body myositis associated with progressive dysphagia: treatment with cricopharyngeal myotomy","volume":"16","author":"M J Danon","year":"1989","journal-title":"Can J Neurol Sci"},{"issue":"09","key":"ref75","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"J C Lega","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"07","key":"ref76","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archdermatol.2010.134","article-title":"Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations","volume":"146","author":"P A Morganroth","year":"2010","journal-title":"Arch Dermatol"},{"issue":"06","key":"ref77","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.berh.2019.03.012","article-title":"Myositis in clinical practice-relevance of new antibodies","volume":"32","author":"S Moghadam-Kia","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"S 05","key":"ref78","first-page":"v1","article-title":"Interstitial lung disease guideline: the British thoracic society in collaboration with the thoracic society of Australia and New Zealand and the Irish thoracic society","volume":"63","author":"B Bradley","year":"2008","journal-title":"Thorax"},{"issue":"05","key":"ref79","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/thoraxjnl-2013-204202","article-title":"Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials","volume":"69","author":"L A Saketkoo","year":"2014","journal-title":"Thorax"},{"issue":"03","key":"ref80","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s11926-011-0169-7","article-title":"Malignancy in myositis","volume":"13","author":"Z A Zahr","year":"2011","journal-title":"Curr Rheumatol Rep"},{"issue":"06","key":"ref81","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/BOR.0b013e32833f1075","article-title":"Malignancy and myositis: novel autoantibodies and new insights","volume":"22","author":"A Selva-O'Callaghan","year":"2010","journal-title":"Curr Opin Rheumatol"},{"issue":"02","key":"ref82","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1203475416665601","article-title":"Risk of malignancy in dermatomyositis and polymyositis","volume":"21","author":"J K Qiang","year":"2017","journal-title":"J Cutan Med Surg"},{"issue":"02","key":"ref83","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40257-015-0120-1","article-title":"Cancer risk in dermatomyositis: a meta-analysis of cohort studies","volume":"16","author":"J M Olazagasti","year":"2015","journal-title":"Am J Clin Dermatol"},{"issue":"06","key":"ref84","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1212\/NXI.0000000000000290","article-title":"Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy","volume":"3","author":"M Kadoya","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"06","key":"ref85","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jaad.2008.09.051","article-title":"Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin","volume":"60","author":"Y Pe\u00f1ate","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"02","key":"ref86","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2019.07.006","article-title":"Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: a review of the literature","volume":"82","author":"H Traineau","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"04","key":"ref88","doi-asserted-by":"crossref","first-page":"552","DOI":"10.4103\/joacp.JOACP_360_19","article-title":"Genetics of malignant hyperthermia: a brief update","volume":"36","author":"D Beebe","year":"2020","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1750-1172-2-21","article-title":"Malignant hyperthermia","volume":"2","author":"H Rosenberg","year":"2007","journal-title":"Orphanet J Rare Dis"},{"issue":"05","key":"ref90","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/00000542-200211000-00007","article-title":"Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility","volume":"97","author":"N Monnier","year":"2002","journal-title":"Anesthesiology"},{"volume-title":"Epidemiology of malignant hyperthermia","year":"2000","author":"H Ording","key":"ref91"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/bja\/34.6.395","article-title":"Anaesthetic deaths in a family","volume":"34","author":"M A Denborough","year":"1962","journal-title":"Br J Anaesth"},{"key":"ref93","first-page":"355","article-title":"Management of malignant hyperthermia: diagnosis and treatment","volume":"10","author":"D Schneiderbanger","year":"2014","journal-title":"Ther Clin Risk Manag"},{"issue":"04","key":"ref94","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF03004694","article-title":"Malignant hyperthermia: a statistical review","volume":"17","author":"B A Britt","year":"1970","journal-title":"Can Anaesth Soc J"},{"issue":"04","key":"ref95","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1213\/ane.0b013e3181ac1548","article-title":"Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005","volume":"109","author":"J E Brady","year":"2009","journal-title":"Anesth Analg"},{"issue":"01","key":"ref96","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/bja\/aer132","article-title":"Malignant hyperthermia: pharmacology of triggering","volume":"107","author":"P M Hopkins","year":"2011","journal-title":"Br J Anaesth"},{"issue":"04","key":"ref97","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/bja\/aeq243","article-title":"Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group","volume":"105","author":"K P Glahn","year":"2010","journal-title":"Br J Anaesth"},{"key":"ref98","first-page":"758","article-title":"Malignant hyperthermia \u2013 diagnostics, treatment and anaesthetic management [article German]","volume":"44","author":"F Schuster","year":"2009","journal-title":"Anasthesiol Intensivmed Notfallmed Schmerzther"},{"issue":"02","key":"ref99","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/cc2978","article-title":"Bench-to-bedside review: rhabdomyolysis \u2013 an overview for clinicians","volume":"9","author":"A L Huerta-Alard\u00edn","year":"2005","journal-title":"Crit Care"},{"issue":"04","key":"ref100","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jcrc.2010.04.002","article-title":"Peak value of blood myoglobin predicts acute renal failure induced by rhabdomyolysis","volume":"25","author":"S Kasaoka","year":"2010","journal-title":"J Crit Care"},{"issue":"01","key":"ref101","first-page":"58","article-title":"Rhabdomyolysis: pathogenesis, diagnosis, and treatment","volume":"15","author":"P A Torres","year":"2015","journal-title":"Ochsner J"},{"issue":"01","key":"ref102","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra0801327","article-title":"Rhabdomyolysis and acute kidney injury","volume":"361","author":"X Bosch","year":"2009","journal-title":"N Engl J Med"},{"issue":"05","key":"ref103","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.amjmed.2006.02.007","article-title":"Clinical perspectives of statin-induced rhabdomyolysis","volume":"119","author":"K A Antons","year":"2006","journal-title":"Am J Med"},{"issue":"10","key":"ref104","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00467-010-1727-3","article-title":"Rhabdomyolysis: pathogenesis of renal injury and management","volume":"26","author":"Z Al-Ismaili","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"03","key":"ref105","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jshs.2015.01.012","article-title":"Exercise-induced rhabdomyolysis mechanisms and prevention: a literature review","volume":"5","author":"J Kim","year":"2016","journal-title":"J Sport Health Sci"},{"issue":"09","key":"ref106","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","article-title":"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors","volume":"94","author":"T A Jacobson","year":"2004","journal-title":"Am J Cardiol"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/DHPS.S333738","article-title":"A narrative review of statin-induced rhabdomyolysis: molecular mechanism, risk factors, and management","volume":"13","author":"N Safitri","year":"2021","journal-title":"Drug Healthc Patient Saf"},{"issue":"01","key":"ref108","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00467-009-1223-9","article-title":"Rhabdomyolysis: a review, with emphasis on the pediatric population","volume":"25","author":"E F Elsayed","year":"2010","journal-title":"Pediatr Nephrol"},{"issue":"06","key":"ref109","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1515\/CCLM.2010.151","article-title":"Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features","volume":"48","author":"G Cervellin","year":"2010","journal-title":"Clin Chem Lab Med"},{"issue":"01","key":"ref110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population frequencies of inherited neuromuscular diseases \u2013 a world survey","volume":"1","author":"A E Emery","year":"1991","journal-title":"Neuromuscul Disord"},{"issue":"02","key":"ref111","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0960-8966(02)00213-4","article-title":"107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands","volume":"13","author":"K Bushby","year":"2003","journal-title":"Neuromuscul Disord"},{"issue":"04","key":"ref112","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"D J Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"06","key":"ref113","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jacc.2004.09.078","article-title":"Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy","volume":"45","author":"D Duboc","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"06","key":"ref114","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.amjcard.2006.04.020","article-title":"Left ventricular function and response to enalapril in patients with Duchenne muscular dystrophy during the second decade of life","volume":"98","author":"C Ramaciotti","year":"2006","journal-title":"Am J Cardiol"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S0140-6736(15)60025-3","article-title":"Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial","volume":"385","author":"G M Buyse","year":"2015","journal-title":"Lancet"},{"issue":"05","key":"ref116","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0960-8966(99)00018-8","article-title":"Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy","volume":"9","author":"E M Hoogerwaard","year":"1999","journal-title":"Neuromuscul Disord"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1046\/j.1460-9592.2000.01661.x","article-title":"High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation","volume":"23","author":"H M B\u00e9cane","year":"2000","journal-title":"Pacing Clin Electrophysiol"},{"issue":"04","key":"ref118","doi-asserted-by":"crossref","first-page":"e0153095","DOI":"10.1371\/journal.pone.0153095","article-title":"Natural history of cardiac and respiratory involvement, prognosis and predictive factors for long-term survival in adult patients with limb girdle muscular dystrophies type 2C and 2D","volume":"11","author":"A Fayssoil","year":"2016","journal-title":"PLoS One"},{"issue":"05","key":"ref119","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/qjmed\/hcm124","article-title":"Cardiac involvement in muscular dystrophies","volume":"101","author":"R P Beynon","year":"2008","journal-title":"QJM"},{"issue":"09","key":"ref120","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/archneur.65.9.1196","article-title":"Cardiac involvement in patients with limb-girdle muscular dystrophy type 2 and Becker muscular dystrophy","volume":"65","author":"M L Sveen","year":"2008","journal-title":"Arch Neurol"},{"issue":"12","key":"ref121","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11940-016-0434-1","article-title":"Myotonic dystrophy type 1 management and therapeutics","volume":"18","author":"C A Smith","year":"2016","journal-title":"Curr Treat Options Neurol"},{"issue":"25","key":"ref122","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1056\/NEJMoa062800","article-title":"Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1","volume":"358","author":"W J Groh","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"ref123","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1001\/jama.2012.346","article-title":"Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease","volume":"307","author":"K Wahbi","year":"2012","journal-title":"JAMA"},{"issue":"07","key":"ref124","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3390\/jcm10071537","article-title":"Drugs that induce or cause deterioration of myasthenia gravis: an update","volume":"10","author":"S Sheikh","year":"2021","journal-title":"J Clin Med"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fnmol.2020.00156","article-title":"Pathomechanisms and clinical implications of myasthenic syndromes exacerbated and induced by medical treatments","volume":"13","author":"M Krenn","year":"2020","journal-title":"Front Mol Neurosci"},{"issue":"03","key":"ref126","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/1559827621993748","article-title":"Five-month trial of whole-food plant-based diet in a patient with coexisting myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"15","author":"P Kim","year":"2021","journal-title":"Am J Lifestyle Med"},{"key":"ref127","first-page":"8781740","article-title":"The effect of immunonutrition on the postoperative complications in thymoma with myasthenia gravis","volume":"2016","author":"Y Xin","year":"2016","journal-title":"Mediators Inflamm"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/1752-1947-4-393","article-title":"Emotional stress as a trigger of myasthenic crisis and concomitant takotsubo cardiomyopathy: a case report","volume":"4","author":"S R Beydoun","year":"2010","journal-title":"J Med Case Reports"},{"issue":"05","key":"ref129","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/HCO.0000000000000437","article-title":"Health benefits of physical activity: a systematic review of current systematic reviews","volume":"32","author":"D ER Warburton","year":"2017","journal-title":"Curr Opin Cardiol"},{"issue":"02","key":"ref130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.7326\/M14-1651","article-title":"Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis","volume":"162","author":"A Biswas","year":"2015","journal-title":"Ann Intern Med"},{"issue":"04","key":"ref131","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.cjca.2016.01.024","article-title":"Reflections on physical activity and health: what should we recommend?","volume":"32","author":"D E Warburton","year":"2016","journal-title":"Can J Cardiol"},{"issue":"01","key":"ref132","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.autrev.2017.11.010","article-title":"Physical activity and autoimmune diseases: get moving and manage the disease","volume":"17","author":"K Sharif","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"01","key":"ref133","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mus.23771","article-title":"Exercise in neuromuscular disease","volume":"48","author":"Y Anziska","year":"2013","journal-title":"Muscle Nerve"},{"issue":"03","key":"ref134","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1378\/chest.128.3.1524","article-title":"Effects of 8-week, interval-based inspiratory muscle training and breathing retraining in patients with generalized myasthenia gravis","volume":"128","author":"G A Fregonezi","year":"2005","journal-title":"Chest"},{"key":"ref135","first-page":"808607","article-title":"Long-term respiratory muscle endurance training in patients with myasthenia gravis: first results after four months of training","volume":"2011","author":"B Rassler","year":"2011","journal-title":"Autoimmune Dis"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.rmed.2018.09.001","article-title":"Effects of long-term respiratory muscle endurance training on respiratory and functional outcomes in patients with Myasthenia gravis","volume":"144","author":"S Freitag","year":"2018","journal-title":"Respir Med"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3389\/fneur.2020.00675","article-title":"Myasthenia gravis and physical exercise: a novel paradigm","volume":"11","author":"L O'Connor","year":"2020","journal-title":"Front Neurol"},{"issue":"03","key":"ref138","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.nmd.2020.12.004","article-title":"Physical training and exercise in myasthenia gravis","volume":"31","author":"N E Gilhus","year":"2021","journal-title":"Neuromuscul Disord"},{"issue":"04","key":"ref139","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000365892","article-title":"Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis","volume":"65","author":"X X Liu","year":"2014","journal-title":"Ann Nutr Metab"},{"issue":"04","key":"ref140","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4158\/EP.12.4.358","article-title":"Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients","volume":"12","author":"A C Donihi","year":"2006","journal-title":"Endocr Pract"},{"issue":"01","key":"ref141","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archinte.1994.00420010131015","article-title":"Glucocorticoids and the risk for initiation of hypoglycemic therapy","volume":"154","author":"J H Gurwitz","year":"1994","journal-title":"Arch Intern Med"},{"issue":"09","key":"ref142","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1525-1497.2002.10649.x","article-title":"Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly","volume":"17","author":"D Blackburn","year":"2002","journal-title":"J Gen Intern Med"},{"issue":"02","key":"ref143","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"D Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref144","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1758-5996-5-18","article-title":"Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients","volume":"5","author":"J G Gonzalez-Gonzalez","year":"2013","journal-title":"Diabetol Metab Syndr"},{"issue":"05","key":"ref145","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4158\/EP08331.RAR","article-title":"Glucocorticoid-induced hyperglycemia","volume":"15","author":"J N Clore","year":"2009","journal-title":"Endocr Pract"},{"issue":"02","key":"ref146","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3346\/jkms.2011.26.2.264","article-title":"Incidence and risk factors of steroid-induced diabetes in patients with respiratory disease","volume":"26","author":"S Y Kim","year":"2011","journal-title":"J Korean Med Sci"},{"issue":"S 01","key":"ref147","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"issue":"10","key":"ref148","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3390\/jcm10102154","article-title":"A practical guide for the management of steroid induced hyperglycaemia in the hospital","volume":"10","author":"F Aberer","year":"2021","journal-title":"J Clin Med"},{"issue":"06","key":"ref149","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/rheumatology\/kes003","article-title":"Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study","volume":"51","author":"M G Burt","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"02","key":"ref150","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"C Farmakidis","year":"2018","journal-title":"Neurol Clin"},{"issue":"01","key":"ref151","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/rheumatology\/keaa209","article-title":"Glucocorticoid use is associated with an increased risk of hypertension","volume":"60","author":"R E Costello","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"01","key":"ref152","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/rheumatology\/kem311","article-title":"Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis","volume":"47","author":"V F Panoulas","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"08","key":"ref153","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0895-7061(95)00149-J","article-title":"Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension","volume":"8","author":"A Sato","year":"1995","journal-title":"Am J Hypertens"},{"issue":"02","key":"ref154","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1677\/JOE-08-0054","article-title":"Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome","volume":"197","author":"D P Macfarlane","year":"2008","journal-title":"J Endocrinol"},{"issue":"06","key":"ref155","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1096\/fj.07-094144","article-title":"AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome","volume":"22","author":"M Christ-Crain","year":"2008","journal-title":"FASEB J"},{"issue":"07","key":"ref156","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/kem062","article-title":"Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome","volume":"46","author":"L Fardet","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"04","key":"ref157","first-page":"400","article-title":"Exercise prevents cardiometabolic alterations induced by chronic use of glucocorticoids","volume":"93","author":"C H Pinheiro","year":"2009","journal-title":"Arq Bras Cardiol"},{"issue":"11","key":"ref158","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.metabol.2011.06.012","article-title":"The effects of glucocorticoids on adipose tissue lipid metabolism","volume":"60","author":"A J Peckett","year":"2011","journal-title":"Metabolism"},{"issue":"07","key":"ref159","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1210\/endo.140.7.6868","article-title":"Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase","volume":"140","author":"I J Bujalska","year":"1999","journal-title":"Endocrinology"},{"issue":"01","key":"ref160","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2133.2007.07950.x","article-title":"Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion","volume":"157","author":"L Fardet","year":"2007","journal-title":"Br J Dermatol"},{"issue":"04","key":"ref161","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jaad.2007.04.018","article-title":"Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study","volume":"57","author":"L Fardet","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"e4928","DOI":"10.1136\/bmj.e4928","article-title":"Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study","volume":"345","author":"L Fardet","year":"2012","journal-title":"BMJ"},{"issue":"03","key":"ref163","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.21984","article-title":"Population-based assessment of adverse events associated with long-term glucocorticoid use","volume":"55","author":"J R Curtis","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"01","key":"ref164","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2265.2012.04348.x","article-title":"Adipokine profile in glucocorticoid-treated patients: baseline plasma leptin level predicts occurrence of lipodystrophy","volume":"78","author":"L Fardet","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"06","key":"ref165","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.berh.2009.09.006","article-title":"Secondary osteoporosis in patients with an osteoporotic fracture","volume":"23","author":"C Kok","year":"2009","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"07","key":"ref166","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1359\/jbmr.070409","article-title":"Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study","volume":"22","author":"J A Cauley","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"12","key":"ref167","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1212\/WNL.0000000000000804","article-title":"Increased risk of osteoporosis in patients with myasthenia gravis: a population-based cohort study","volume":"83","author":"J H Yeh","year":"2014","journal-title":"Neurology"},{"issue":"03","key":"ref168","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1359\/JBMR.041125","article-title":"Effects of low-dose prednisone on bone metabolism","volume":"20","author":"F N Ton","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"03","key":"ref169","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1359\/JBMR.0301242","article-title":"Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k","volume":"19","author":"Y Liu","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"10","key":"ref170","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1210\/jc.2005-0646","article-title":"Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression","volume":"90","author":"H Russcher","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"ref171","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"T P van Staa","year":"2002","journal-title":"Osteoporos Int"},{"issue":"06","key":"ref172","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"T P Van Staa","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"06","key":"ref173","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","article-title":"A meta-analysis of prior corticosteroid use and fracture risk","volume":"19","author":"J A Kanis","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"02","key":"ref174","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bone.2006.02.005","article-title":"High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study","volume":"39","author":"A Angeli","year":"2006","journal-title":"Bone"},{"issue":"11","key":"ref175","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","article-title":"Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy","volume":"48","author":"T P Van Staa","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"03","key":"ref176","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/qjmed\/hci029","article-title":"A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids","volume":"98","author":"T P van Staa","year":"2005","journal-title":"QJM"},{"issue":"06","key":"ref177","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jbspin.2014.10.001","article-title":"2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"81","author":"K Briot","year":"2014","journal-title":"Joint Bone Spine"},{"issue":"08","key":"ref178","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"L Buckley","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"09","key":"ref179","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1056\/NEJM197602262940905","article-title":"Nonassociation of adrenocorticosteroid therapy and peptic ulcer","volume":"294","author":"H O Conn","year":"1976","journal-title":"N Engl J Med"},{"issue":"01","key":"ref180","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM198307073090105","article-title":"Association of adrenocorticosteroid therapy and peptic-ulcer disease","volume":"309","author":"J Messer","year":"1983","journal-title":"N Engl J Med"},{"issue":"06","key":"ref181","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2796.1994.tb00855.x","article-title":"Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy","volume":"236","author":"H O Conn","year":"1994","journal-title":"J Intern Med"},{"issue":"05","key":"ref182","doi-asserted-by":"crossref","first-page":"e004587","DOI":"10.1136\/bmjopen-2013-004587","article-title":"Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis","volume":"4","author":"S Narum","year":"2014","journal-title":"BMJ Open"},{"issue":"02","key":"ref183","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/ijcp.12039","article-title":"The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic","volume":"67","author":"M Smith","year":"2013","journal-title":"Int J Clin Pract"},{"issue":"04","key":"ref184","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1053\/j.gastro.2006.01.046","article-title":"Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis","volume":"130","author":"M T Osterman","year":"2006","journal-title":"Gastroenterology"},{"issue":"03","key":"ref185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: Association of British Neurologists' management guidelines","volume":"15","author":"J Sussman","year":"2015","journal-title":"Pract Neurol"},{"issue":"06","key":"ref186","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/rheumatology\/kew479","article-title":"BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs","volume":"56","author":"J Ledingham","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"01","key":"ref187","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/flgastro-2016-100738","article-title":"A practical guide to thiopurine prescribing and monitoring in IBD","volume":"9","author":"B Warner","year":"2018","journal-title":"Frontline Gastroenterol"},{"issue":"01","key":"ref188","first-page":"69","article-title":"Azathioprine and the neurologist","volume":"20","author":"M McWilliam","year":"2020","journal-title":"Pract Neurol"},{"key":"ref189","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1097\/01.tp.0000186390.10150.66","article-title":"Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection","volume":"80","author":"A C Allison","year":"2005","journal-title":"Transplantation"},{"issue":"02","key":"ref190","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000050768","article-title":"Mycophenolate mofetil in the therapy of severe myasthenia gravis","volume":"46","author":"C Schneider","year":"2001","journal-title":"Eur Neurol"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"D M Roberts","year":"2015","journal-title":"J Autoimmun"},{"issue":"03","key":"ref192","doi-asserted-by":"crossref","first-page":"102466","DOI":"10.1016\/j.autrev.2020.102466","article-title":"Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia","volume":"19","author":"K Kridin","year":"2020","journal-title":"Autoimmun Rev"},{"key":"ref193","doi-asserted-by":"crossref","first-page":"671503","DOI":"10.3389\/fimmu.2021.671503","article-title":"Rituximab associated hypogammaglobulinemia in autoimmune disease","volume":"12","author":"J Tieu","year":"2021","journal-title":"Front Immunol"},{"key":"ref194","first-page":"616787","article-title":"Early-onset neutropenia induced by rituximab in a patient with lupus nephritis and hemolytic anemia","volume":"2015","author":"M Arroyo-\u00c1vila","year":"2015","journal-title":"Case Rep Rheumatol"},{"key":"ref195","first-page":"ECR23","article-title":"Rituximab-induced acute thrombocytopenia: a report of two cases","volume":"90","author":"Z K Otrock","year":"2005","journal-title":"Haematologica"},{"issue":"27","key":"ref199","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"L A McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"volume-title":"Avis: actualisation de l'avis relatif \u00e0 l'antibioprophylaxie et la vaccination m\u00e9ningococcique des personnes trait\u00e9es par eculizumab (Soliris 300\u2009mg solution \u00e0 diluer pour perfusion) [French]","year":"2017","author":"Haut Conseil de la sant\u00e9 publique","key":"ref200"},{"issue":"02","key":"ref202","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00441919","article-title":"Clinical trials of sulfonated immunoglobulin preparation for intravenous administration. II. Adverse reactions","volume":"136","author":"S Matsumoto","year":"1981","journal-title":"Eur J Pediatr"},{"issue":"03","key":"ref203","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2340\/00015555-1471","article-title":"Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events","volume":"93","author":"V Seidling","year":"2013","journal-title":"Acta Derm Venereol"},{"issue":"03","key":"ref204","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1542\/peds.2007-1218","article-title":"Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content","volume":"121","author":"C Manlhiot","year":"2008","journal-title":"Pediatrics"},{"issue":"04","key":"ref205","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1046\/j.1537-2995.1997.37497265353.x","article-title":"Clinical impact of anti-D in intravenous immunoglobulin","volume":"37","author":"D F Friedman","year":"1997","journal-title":"Transfusion"},{"issue":"03","key":"ref206","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaci.2011.06.047","article-title":"The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature","volume":"129","author":"R Rachid","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"ref207","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Y Guo","year":"2018","journal-title":"Front Immunol"},{"issue":"03","key":"ref208","first-page":"174","article-title":"Use of methylprednisolone as prophylaxis for immediate adverse infusion reactions in hypogammaglobulinaemic patients receiving intravenous immunoglobulin: a controlled trial","volume":"24","author":"D M Roberton","year":"1988","journal-title":"Aust Paediatr J"},{"issue":"06","key":"ref209","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/mus.25409","article-title":"Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: a meta-analysis","volume":"55","author":"J M Racosta","year":"2017","journal-title":"Muscle Nerve"},{"issue":"06","key":"ref210","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0272-6386(12)80135-1","article-title":"Therapeutic plasma exchange: complications and management","volume":"23","author":"M H Mokrzycki","year":"1994","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"ref211","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1046\/j.1537-2995.1994.341095026976.x","article-title":"Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis","volume":"34","author":"H G Owen","year":"1994","journal-title":"Transfusion"},{"volume-title":"Plasmapheresis","year":"2022","author":"S R Sergent","key":"ref212"},{"issue":"04","key":"ref213","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/jca.21975","article-title":"Central venous catheters are associated with thrombosis among adult inpatients undergoing therapeutic plasma exchange","volume":"37","author":"A Soares Ferreira J\u00fanior","year":"2022","journal-title":"J Clin Apher"},{"issue":"03","key":"ref214","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-0036-1596064","article-title":"Catheter-associated blood stream infections in intracardiac lines","volume":"6","author":"X Garcia","year":"2017","journal-title":"J Pediatr Intensive Care"},{"issue":"10","key":"ref215","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1111\/trf.14248","article-title":"Central venous catheter placement in coagulopathic patients: risk factors and incidence of bleeding complications","volume":"57","author":"E K van de Weerdt","year":"2017","journal-title":"Transfusion"},{"volume-title":"Central Venous Catheter. In: StatPearls [Internet]","year":"2022","author":"J Kolikof","key":"ref216"},{"issue":"08","key":"ref217","first-page":"13990","article-title":"Preoperative risk factors for prolonged postoperative ventilation following thymectomy in myasthenia gravis","volume":"8","author":"W Lu","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"06","key":"ref218","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/icvts\/ivz186","article-title":"Clinical usefulness of prethymectomy plasmapheresis in patients with myasthenia gravis: a systematic review and meta-analysis","volume":"29","author":"T A Reis","year":"2019","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"ref219","doi-asserted-by":"crossref","first-page":"1756286419864497","DOI":"10.1177\/1756286419864497","article-title":"Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis","volume":"12","author":"J Gamez","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"01","key":"ref220","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13760-016-0689-z","article-title":"A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients","volume":"117","author":"A Alipour-Faz","year":"2017","journal-title":"Acta Neurol Belg"},{"issue":"03","key":"ref221","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/CND.0b013e3181660807","article-title":"A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis","volume":"9","author":"P Jensen","year":"2008","journal-title":"J Clin Neuromuscul Dis"},{"issue":"02","key":"ref222","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.intimp.2014.09.015","article-title":"Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions","volume":"23","author":"D C Bichuetti-Silva","year":"2014","journal-title":"Int Immunopharmacol"},{"issue":"02","key":"ref223","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12028-015-0115-z","article-title":"Transfusion-related acute lung injury after IVIG for myasthenic crisis","volume":"23","author":"D R Reddy","year":"2015","journal-title":"Neurocrit Care"},{"issue":"03","key":"ref224","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12288-015-0604-4","article-title":"Transfusion related acute lung injury (TRALI): a single institution experience of 15 years","volume":"32","author":"R Kumar","year":"2016","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref225","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1212\/WNL.59.12_suppl_6.S33","article-title":"Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies","volume":"59","author":"T H Brannagan III","year":"2002","journal-title":"Neurology"},{"issue":"01","key":"ref226","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejim.2008.04.022","article-title":"Intravenous immunoglobulins-induced eczematous eruption: a long-term follow-up study","volume":"20","author":"F Cohen Aubart","year":"2009","journal-title":"Eur J Intern Med"},{"issue":"10","key":"ref227","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/j.1537-2995.2012.03589.x","article-title":"Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010","volume":"52","author":"G W Daniel","year":"2012","journal-title":"Transfusion"},{"issue":"06","key":"ref228","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.thromres.2014.03.046","article-title":"Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study","volume":"133","author":"E Ram\u00edrez","year":"2014","journal-title":"Thromb Res"},{"key":"ref229","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jns.2011.05.035","article-title":"Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study","volume":"308","author":"Y A Rajabally","year":"2011","journal-title":"J Neurol Sci"},{"issue":"04","key":"ref230","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"E A Sekul","year":"1994","journal-title":"Ann Intern Med"},{"issue":"11","key":"ref231","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1111\/trf.13200","article-title":"Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: a retrospective review at a single tertiary care center","volume":"55","author":"V Bharath","year":"2015","journal-title":"Transfusion"},{"issue":"09","key":"ref232","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.05.034","article-title":"Posterior reversible encephalopathy syndrome and stroke after intravenous immunoglobulin treatment in Miller-Fisher syndrome\/Bickerstaff brain stem encephalitis overlap syndrome","volume":"23","author":"H R Stetefeld","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"06","key":"ref233","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/mus.25693","article-title":"Renal and hematologic side effects of long-term intravenous immunoglobulin therapy in patients with neurologic disorders","volume":"56","author":"A A Levine","year":"2017","journal-title":"Muscle Nerve"},{"issue":"02","key":"ref234","first-page":"60","article-title":"Important drug warning: immune globulin intravenous (human) (IGIV) products","volume":"19","author":"J S Epstein","year":"2000","journal-title":"Neonatal Netw"}],"container-title":["Seminars in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1758779.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T06:41:03Z","timestamp":1671000063000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1758779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":229,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2022,12,13]]},"published-print":{"date-parts":[[2022,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1758779","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0271-8235","1098-9021"],"issn-type":[{"type":"print","value":"0271-8235"},{"type":"electronic","value":"1098-9021"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}